4565 Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,731.00 |
52 Week High | JP¥1,826.00 |
52 Week Low | JP¥1,296.00 |
Beta | 0.70 |
11 Month Change | 2.43% |
3 Month Change | 21.13% |
1 Year Change | 5.74% |
33 Year Change | -2.09% |
5 Year Change | -24.15% |
Change since IPO | -14.94% |
Recent News & Updates
Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable
Jun 26Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Shareholder Returns
4565 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 5.0% | 2.9% | 0.5% |
1Y | 5.7% | 21.9% | 16.4% |
Return vs Industry: 4565 underperformed the JP Pharmaceuticals industry which returned 21.9% over the past year.
Return vs Market: 4565 underperformed the JP Market which returned 16.4% over the past year.
Price Volatility
4565 volatility | |
---|---|
4565 Average Weekly Movement | 5.9% |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 10.1% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4565 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4565's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 350 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
4565 fundamental statistics | |
---|---|
Market cap | JP¥155.62b |
Earnings (TTM) | -JP¥9.84b |
Revenue (TTM) | JP¥23.34b |
6.7x
P/S Ratio-15.8x
P/E RatioIs 4565 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4565 income statement (TTM) | |
---|---|
Revenue | JP¥23.34b |
Cost of Revenue | JP¥6.37b |
Gross Profit | JP¥16.97b |
Other Expenses | JP¥26.81b |
Earnings | -JP¥9.84b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -109.41 |
Gross Margin | 72.71% |
Net Profit Margin | -42.14% |
Debt/Equity Ratio | 96.1% |
How did 4565 perform over the long term?
See historical performance and comparison